These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

705 related items for PubMed ID: 28845713

  • 1. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
    Zhang J, Liang Y, Ai Y, Xie J, Li Y, Zheng W.
    Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713
    [Abstract] [Full Text] [Related]

  • 2. Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis.
    Zhang J, Liang Y, Ai Y, Li X, Xie J, Li Y, Zheng W, He R.
    PLoS One; 2018 Oct; 13(6):e0198504. PubMed ID: 29856837
    [Abstract] [Full Text] [Related]

  • 3. Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis.
    Zhang J, Liang Y, Ai Y, Li X, Xie J, Li Y, Zheng W, He R.
    Sci Rep; 2018 Jan 12; 8(1):576. PubMed ID: 29330464
    [Abstract] [Full Text] [Related]

  • 4. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura.
    Zeng Y, Duan X, Xu J, Ni X.
    Cochrane Database Syst Rev; 2011 Jul 06; 2011(7):CD008235. PubMed ID: 21735426
    [Abstract] [Full Text] [Related]

  • 5. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
    Lassandro G, Palladino V, Vecchio GCD, Palmieri VV, Corallo PC, Faienza MF, Giordano P.
    Endocr Metab Immune Disord Drug Targets; 2021 Jul 06; 21(3):397-406. PubMed ID: 32473624
    [Abstract] [Full Text] [Related]

  • 6. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV, Vinogradova OY, Pankrashkina MM, Chernikov MV, Arshanskaya EG, Tkachenko NE.
    Ter Arkh; 2018 Aug 17; 90(7):70-76. PubMed ID: 30701925
    [Abstract] [Full Text] [Related]

  • 7. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
    Tremblay G, Dolph M, Roy AN, Said Q, Forsythe A.
    Clin Ther; 2020 May 17; 42(5):860-872.e8. PubMed ID: 32199608
    [Abstract] [Full Text] [Related]

  • 8. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.
    Neunert C, Despotovic J, Haley K, Lambert MP, Nottage K, Shimano K, Bennett C, Klaassen R, Stine K, Thompson A, Pastore Y, Brown T, Forbes PW, Grace RF, Pediatric ITP Consortium of North America (ICON).
    Pediatr Blood Cancer; 2016 Aug 17; 63(8):1407-13. PubMed ID: 27135461
    [Abstract] [Full Text] [Related]

  • 9. Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists.
    Forsythe A, Schneider J, Pham T, Bhor M, Said Q, Allepuz A, Socorro O Portella MD, Kwon CS, Roy AN.
    J Comp Eff Res; 2020 May 17; 9(7):447-457. PubMed ID: 32175766
    [Abstract] [Full Text] [Related]

  • 10. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K.
    Clin J Oncol Nurs; 2019 Apr 01; 23(2):212-216. PubMed ID: 30880797
    [Abstract] [Full Text] [Related]

  • 11. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.
    Puavilai T, Thadanipon K, Rattanasiri S, Ingsathit A, McEvoy M, Attia J, Thakkinstian A.
    Br J Haematol; 2020 Feb 01; 188(3):450-459. PubMed ID: 31423574
    [Abstract] [Full Text] [Related]

  • 12. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F, Barcellini W, Cantoni S, Carpenedo M, Caparrotti G, Carrai V, Di Renzo N, Santoro C, Di Nicola M, Veneri D, Simonetti F, Liberati AM, Ferla V, Paoloni F, Crea E, Volpetti S, Tuniz E, Fanin R.
    Am J Hematol; 2016 May 01; 91(5):E293-5. PubMed ID: 26910388
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials.
    Catalá-López F, Corrales I, Martín-Serrano G, Tobías A, Calvo G.
    Med Clin (Barc); 2012 Oct 20; 139(10):421-9. PubMed ID: 22266082
    [Abstract] [Full Text] [Related]

  • 15. A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists.
    Dolph M, Roy A, Bhor M, Hearnden J, Kwon CS, Forsythe A, Tremblay G, Briggs A.
    J Comp Eff Res; 2018 Aug 20; 7(8):775-784. PubMed ID: 29848048
    [Abstract] [Full Text] [Related]

  • 16. Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study.
    Cooper N, Scully M, Percy C, Nicolson PLR, Lowe G, Bagot CN, Thachil J, Grech H, Nokes T, Hill QA, Bradbury C, Talks K, Dutt T, Evans G, Pavord S, Wexler S, Charania A, Collington SJ, Ervin A, Ramscar N, Provan D.
    Br J Haematol; 2024 Jun 20; 204(6):2442-2452. PubMed ID: 38429869
    [Abstract] [Full Text] [Related]

  • 17. Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.
    Neunert CE.
    Hamostaseologie; 2019 Aug 20; 39(3):272-278. PubMed ID: 30646404
    [Abstract] [Full Text] [Related]

  • 18. Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.
    Meyer O, Salama A.
    Onkologie; 2011 Aug 20; 34(1-2):10-3. PubMed ID: 21346379
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.